68Ga-PSMA PET/CT靶向穿刺对比经直肠超声引导穿刺诊断临床显著前列腺癌的前瞻性随机单中心研究
该单中心前瞻性随机研究将120例血清PSA>4 ng/ml患者随机分入PSMA-PET组或TRUS组,评估68Ga-PSMA-11 PET/CT作为前列腺穿刺分诊工具的诊断效能。PSMA-PET组PCa和csPCa检出率分别为43.3%和40.0%,TRUS组分别为31.6%和25.0%;PSMA-TB在TRUS对照中检出PCa和csPCa显著高于TRUS-GB。结论认为68Ga-PSMA-11 PET/CT可作为穿刺分诊工具,尤其在PSA 4.0-20.0 ng/ml患者中提高csPCa检出率。
要点
- PSMA-PET组PCa和csPCa检出率分别为43.3%和40.0%,高于TRUS组的31.6%和25.0%。
- PSMA-PET阳性患者PCa和csPCa检出率显著高于阴性患者(92.0% vs 8.6%;88.0% vs 5.7%)。
- PSA 4.0-20.0 ng/ml患者中PSMA-PET检出csPCa显著多于TRUS(27.02% vs 8.82%)。
核心结论
- 68Ga-PSMA-11 PET/CT是可行的影像技术,可能作为前列腺穿刺的分诊工具。
- 与TRUS-GB相比,PSMA-TB可能提高csPCa检出率,尤其在血清PSA 4.0-20.0 ng/ml患者中。
研究设计与样本
- 单中心前瞻性随机研究,120例血清PSA>4 ng/ml患者随机分入PSMA-PET组或TRUS组。
- PSMA-PET组中PSMA阳性(SUVmax≥8.0)者行经单点经臀穿刺PSMA-TB(n=25),PSMA-PET阴性者行系统性TRUS-GB(n=35)。
- TRUS组患者直接行TRUS-GB(n=60)。
主要发现
- PSMA-PET组PCa检出26/60(43.3%)、csPCa检出24/60(40.0%);TRUS组分别为19/60(31.6%)和15/60(25.0%)。
- PSMA-PET组中阳性患者PCa检出23/25(92.0%)高于阴性患者3/35(8.6%),P<0.01。
- PSMA-PET组中阳性患者csPCa检出22/25(88.0%)高于阴性患者2/35(5.7%),P<0.01。
- PSMA-TB对比TRUS对照的PCa检出为21/25(84.0%)vs 19/60(31.6%),P<0.01;csPCa为20/25(80.0%)vs 15/60(25.0%),P<0.01。
- PSA 4.0-20.0 ng/ml患者中PSMA-PET检出csPCa为27.02%,TRUS为8.82%,P<0.05。
关键数值与推荐
- PSMA-avid病灶定义为SUVmax≥8.0,阳性者行PSMA-TB。
- 入组条件为血清PSA>4 ng/ml。
- PSMA-TB后未观察到血尿、尿潴留或盆腔感染,与TRUS-GB相比无上述并发症。
临床怎么用
- 68Ga-PSMA-11 PET/CT可作为前列腺穿刺的分诊工具,指导是否行靶向穿刺。
- 对PSA 4.0-20.0 ng/ml患者,PSMA-PET分诊可能提高csPCa检出率。
局限性
- 单中心研究,样本量有限(共120例)。
- PSMA-PET组中阴性患者仍行系统性TRUS-GB,阳性者仅行PSMA-TB,两组穿刺方式不完全对等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is valuable for detecting primary and recurrent prostatic lesions. This study aimed to evaluate the efficacy of 68Ga-PSMA-11 PET/CT as a triage tool for prostate biopsy (PSMA-TB) and compare with transrectal ultrasound-guided biopsy (TRUS-GB) for the diagnosis of clinically significant prostate cancer (csPCa). METHODS: This single-centre study randomly allocated 120 patients with elevated serum prostate-specific antigen (PSA) levels (> 4 ng/ml) to PSMA-PET or TRUS group. Patients with PSMA-avid lesions (SUVmax ≥ 8.0) underwent PSMA-TB via a single-puncture percutaneous transgluteal approach (n = 25), whilst patients with negative PSMA-PET underwent systematic TRUS-GB (n = 35). All patients in the TRUS group underwent TRUS-GB directly (n = 60). RESULTS: PCa and csPCa were detected in 26/60 (43.3%) and 24/60 (40.0%) patients in the PSMA-PET group and 19/60 (31.6%) and 15/60 (25.0%) in the TRUS group, respectively. In the PSMA-PET group, the detection rate of PCa and csPCa were significantly higher in PSMA-PET-positive than negative patients (PCa, 23/25 (92.0%) vs 3/35 (8.6%), P < 0.01; csPCa, 22/25 (88.0%) vs 2/35 (5.7%), P < 0.01). PSMA-TB detected significantly more PCa and csPCa than TRUS-GB in the TRUS controls (PCa, 21/25 (84.0%) vs 19/60 (31.6%), P < 0.01; csPCa, 20/25 (80.0%) vs 15/60 (25.0%), P < 0.01). PSMA-PET detected significantly more cases of csPCa amongst patients with PSA 4.0-20.0 ng/ml than TRUS (27.02% vs 8.82%, P < 0.05). No haematuria, urinary retention or pelvic infection was observed after PSMA-TB compare with TRUS-GB. CONCLUSIONS: 68Ga-PSMA-11 PET/CT is a feasible imaging technique that may serve as a triage tool for prostate biopsy, and may improve the detection rate of csPCa compared with TRUS-GB, especially in patients with serum PSA 4.0-20.0 ng/ml.
引用
- Zhang LL, Li WC, Xu Z, et al. 68Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study. Eur J Nucl Med Mol Imaging. 2020. PMID: 32734457. doi:10.1007/s00259-020-04863-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。